The Chicago Technology Park
|
|
| 2201 W. Campbell Park Dr. Suite 1 |
| Chicago, IL 60612 |
| 312-829-7252 |
|
| www.techpark.com |
|
|
 |
| Abstract Description |
| The Chicago Technology Park is a 56-acre research park that fosters the commercialization of innovative technologies through state-of-the-art facilities and critical support services. |
 |
| Management |
President-Samuel Pruett
Director of Marketing-Rachael Garcia |
|
|
|
|
|
| Keywords |
| business incubator, life science, start-up companies, facilities, support, laboratory, nutrition, chemical, agdnutrition, antivirals, human pathogenic viruses, Biochem, isotopes, ioresistance technologies, bioresistant materials, bioinformatics training, BiTmaP, Charles River Laboratories, Cobrek Pharmaceuticals, prescription drug therapies, CorDynamics, research, cardiovascular, Creatv MicroTech, x-ray, Crison, buffers and amino acid derivatives, Fermalogic, microbiology, genetics, Glycopep, drug discovery, The Hektoen Institute of Medicine, education, HumanZyme USA, human proteins, human cells,
|
|
|
|
|
|
|
|
|
network/Communities, Consulting and Advisory, Education and Technology, Legal and Regulatory, Operations, Research Testing and Trials/Incubator, Education/Training, Research Centers, Clinical Testing
|
| |
|
Description |
| The CTP's dynamic community helps to fulfill its mission to assist in the growth of life science companies and to help life science businesses flourish. By supplying fully equipped infrastructure and access to university resources, internship programs, world-class talent, and custom designed business development services, the CTP works to ensure the success of the companies that make up its community. |
|
Customers/Clients |
Identifies niche products in the nutrition and fine chemical industry where it can develop technology to permit cost effective manufacturing and marketing of products used in human and animal health.
Antivirals, LLC
Discovery of agents that inhibit replication of human pathogenic viruses
Cobrek Pharmaceuticals, Inc.
Research, development and commercialization of novel prescription drug therapies, delivery systems and applications that improve quality of life and enhance the lifestyle of patients across the adolescent and adult age-spectrum with particular attention to the needs of the aging population |
|
|
|
|
